Quick Answer
RIGEL PHARMACEUTICALS INC reported Revenue From Contract With Customer Excluding Assessed Tax of $294.28 million for the year ending 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +64.1% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from RIGEL PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), RIGEL PHARMACEUTICALS INC's Revenue From Contract With Customer Excluding Assessed Tax has grown by 1,343.8%.
- Historical annual values: Fiscal year 2025: $294.28 million | Fiscal year 2024: $179.28 million | Fiscal year 2023: $116.88 million | Fiscal year 2022: $120.24 million | Fiscal year 2021: $149.24 million | Fiscal year 2020: $108.62 million | Fiscal year 2019: $59.29 million | Fiscal year 2018: $44.51 million | Fiscal year 2017: $4.48 million | Fiscal year 2016: $20.38 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: